Stem Cells and Spinal Cord Injury: What Research Shows and What Clinics Claim

Why we wrote this article the way we did

HealthBridge does not offer stem cell therapy for spinal cord injury, and this article is not a sales page. We wrote it because people searching this topic are among the most vulnerable patients on the internet, and much of what they will find is written by clinics with a financial interest in their hope. If this page persuades you to be more skeptical and to keep your money, it has done its job.

Spinal cord injury is devastating and permanent in a way few conditions are. It typically affects young, previously healthy people, and it changes mobility, independence, bladder and bowel function, sexual function and often sensation, in an instant. Existing medicine offers rehabilitation, adaptive technology, complication prevention and extraordinary human adaptation — but not repair. The desire for something that would restore what was lost is completely rational.

That desire is precisely what a global industry of unregulated clinics has monetized. Families remortgage homes and run crowdfunding campaigns to pay for treatments that have never been shown to work, sometimes with serious harm. So the most useful thing an honest medical site can publish about this topic is not encouragement. It is an accurate picture of where the science actually stands, and a clear description of how the exploitation works. Our guide to stem cell safety and scams is the companion piece.

Why spinal cord injury is so biologically difficult

Understanding why this is hard helps you evaluate claims. The spinal cord is central nervous system tissue, which regenerates far less readily than peripheral nerves. After injury, several problems compound. Neurons and their long axons are damaged or severed, and those axons may need to regrow over considerable distances. A glial scar forms at the injury site, which stabilizes the area but also creates a physical and chemical barrier to regrowth. The local environment contains molecules that actively inhibit axon extension. And even if fibers did regrow, they would need to reconnect to the correct targets in the correct pattern to restore useful function.

That is four distinct problems, each individually unsolved in humans. A therapy would need to protect surviving tissue, overcome inhibition, guide regrowth across the lesion, and achieve appropriate reconnection. No injected cell population currently accomplishes this, and describing the challenge accurately makes clear why the field's progress has been slower than anyone wants.

It is also why the distinction between complete and incomplete injury matters in any honest discussion. Incomplete injuries, where some neural connection across the lesion persists, retain more potential for functional gain, especially with intensive rehabilitation that exploits surviving pathways. Complete injuries with no preserved connection are a much harder biological problem. Clinics rarely make this distinction, which is itself informative.

What legitimate research is actually doing

Real science is happening here, and it deserves to be distinguished from clinic marketing. Registered clinical trials have investigated several approaches: neural stem or progenitor cells, oligodendrocyte precursor cells intended to support remyelination, Schwann cells, mesenchymal stem cells for their anti-inflammatory signaling, and combination strategies pairing cells with scaffolds or rehabilitation protocols. Trials have examined both acute and chronic injury, and various delivery routes.

The results so far are best described as preliminary and cautious. Studies have generally focused on safety and feasibility, and some have reported modest changes in specific measures in some participants. What has not happened is a trial demonstrating substantial, reproducible restoration of function that has led to an approved treatment. Regulatory agencies have not approved a stem cell therapy as an established treatment for spinal cord injury.

For a patient, the meaningful implication is that a registered clinical trial is the appropriate route if you want to engage with this field. Trials provide ethical oversight, informed consent processes, structured monitoring for harm, and a contribution to knowledge that helps future patients. They generally do not charge you tens of thousands of dollars. If a clinic offers the same category of intervention for a large fee outside any research framework, ask why it is not being studied properly — and treat the answer as data about the clinic.

How the exploitation works, and its real risks

The pattern is consistent enough to be recognizable. Marketing features dramatic video testimonials rather than published data. Claims are made about restoring movement or sensation. Many unrelated serious conditions are treated with the same protocol. Costs are high and payment is requested upfront, often with urgency. Sourcing of cells is described vaguely. The treating physician may not be clearly named. And the treatment is presented as available now, unlike the "slow" research establishment — a framing designed to convert frustration with science into a purchase.

The harms are not merely financial. Injections into the intrathecal space or directly into the spinal cord are invasive procedures with genuine risk, including infection, meningitis, bleeding, worsening neurological function, and the growth of abnormal tissue masses at injection sites, which has been documented in the medical literature following treatment at unregulated clinics. These are not theoretical concerns raised to discourage patients; they are reported outcomes.

There is also the opportunity cost, which families often recognize only afterward. Money spent on an unproven infusion is money not spent on rehabilitation, equipment, home modification, accessible transport or personal support — all of which have measurable effects on independence and quality of life. And there is emotional cost: the cycle of hope, expense, disappointment and sometimes guilt is genuinely damaging to families already under strain.

Where meaningful gains actually come from

It would be a poor article that only said no. Real improvements in function and quality of life after spinal cord injury do happen, and they come from areas that receive less attention than experimental biology. Intensive, specialized rehabilitation is the foundation, particularly for incomplete injuries where activity-based therapy targeting surviving pathways can produce meaningful gains, sometimes well beyond the first year.

Technology has also changed what is possible: advanced wheelchairs and seating, functional electrical stimulation, exoskeletons in specific contexts, and adaptive equipment for driving, work and daily living. Research into epidural spinal stimulation has produced some of the most genuinely interesting findings in the field, with participants in studies recovering elements of voluntary movement or standing — still research, but research grounded in published data rather than testimonials.

Equally important and less discussed is preventing secondary complications, which drive much of the long-term morbidity: pressure injuries, urinary tract infections, autonomic dysreflexia, spasticity, respiratory complications and neuropathic pain. Managing these well has a larger effect on daily life than most people expect. Our articles on spinal cord stimulation and chronic pain management cover related ground for people living with neurological pain.

What to do if you are still considering treatment

If, having read all of this, you or your family are still considering a stem cell treatment for spinal cord injury, a few steps will protect you. Ask whether the treatment is part of a registered clinical trial, and if not, why not. Ask the clinic to state in writing that the therapy is investigational and that they do not guarantee functional recovery. Ask what specific outcome they expect for your injury level and completeness — a clinic that cannot discuss ASIA classification meaningfully is not equipped to treat you.

Ask what the procedure involves and what its specific risks are, particularly for intrathecal or intraspinal delivery. Ask who administers it and verify their license. Ask what happens if there is no benefit, and whether any portion of the cost is refundable. Consult your own spinal specialist before committing, and be honest with them about what you are considering; a good physician would rather advise you than have you go quietly.

At HealthBridge, we do not offer stem cell therapy for spinal cord injury, and we will tell any patient who asks that we believe the honest answer is that no proven treatment exists. Our medical director Dra. Olga González leads a regenerative program where we describe applications as investigational when they are, and where we decline treatments we do not believe are appropriate. Our regenerative medicine page sets out where we think the evidence genuinely supports treatment, and that boundary is the whole point of publishing an article like this one.